{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:39:26Z","timestamp":1786991966965,"version":"build-2736575974"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jdcr.2024.08.002","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T03:06:43Z","timestamp":1724987203000},"page":"102-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The utility of upadacitinib to treat refractory hidradenitis suppurativa in an obese patient"],"prefix":"10.1016","volume":"65","author":[{"given":"Zahidul","family":"Islam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Y.","family":"Ch\u2019en","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solbie","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Oprea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Campton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.jdcr.2024.08.002_bib1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.31138\/mjr.31.1.100","article-title":"Basic mechanisms of JAK inhibition","volume":"31","author":"Lin","year":"2020","journal-title":"Mediterr J Rheumatol"},{"issue":"3","key":"10.1016\/j.jdcr.2024.08.002_bib2","doi-asserted-by":"crossref","first-page":"AB42","DOI":"10.1016\/j.jaad.2023.07.172","article-title":"43799 efficacy and safety of upadacitinib in moderate-to-severe hidradenitis suppurativa: a phase 2, randomized, placebo-controlled study","volume":"89","author":"Kimball","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jdcr.2024.08.002_bib3","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jaad.2022.07.047","article-title":"Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: a retrospective cohort study","volume":"87","author":"Kozera","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jdcr.2024.08.002_bib4","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jid.2023.07.023","article-title":"Rapid attenuation of B-cell and IFN-\u03b3-Associated chemokines in clinical responders to jak inhibition with upadacitinib in hidradenitis suppurativa","volume":"144","author":"Flora","year":"2024","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.jdcr.2024.08.002_bib5","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/ijd.16565","article-title":"Adalimumab efficacy is inversely correlated with body mass index (BMI) in hidradenitis suppurativa","volume":"62","author":"Nosrati","year":"2023","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.jdcr.2024.08.002_bib6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/jvc2.139","article-title":"Serum infliximab levels and clinical response in hidradenitis suppurativa","volume":"2","author":"Benassaia","year":"2023","journal-title":"JEADV Clin Pract"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624003199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624003199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T21:34:43Z","timestamp":1765316083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512624003199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":6,"alternative-id":["S2352512624003199"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.08.002","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The utility of upadacitinib to treat refractory hidradenitis suppurativa in an obese patient","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}